Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGILENT TECHNOLOGIES, INC.

(A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agilent Technologies : PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)

07/20/2021 | 12:16pm EST

Agilent Technologies Inc. (NYSE: A) today announced that the company's PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union. PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab). This announcement underscores Agilent's continuing commitment to the development of IHC-based diagnostics for cancer therapy.

Lung cancer is the leading cause of cancer death overall and the 2nd most commonly diagnosed cancer in Europe.1 NSCLC makes up approximately 85% of all lung cancer cases.2 In Europe, the average five-year survival rate for lung cancer is less than 20%.3

'This expanded indication for PD-L1 IHC 22C3 pharmDx will enable pathologists in Europe to identify patients with NSCLC who may be eligible for treatment with Libtayo,' said Sam Raha, president of Agilent's Diagnostics and Genomics Group. 'This further demonstrates Agilent's commitment to partnering with leading pharmaceutical companies to develop IHC-based diagnostics for targeted cancer therapy.'

Anti-PD-1 immunotherapies such as Libtayo offer new treatment options for patients with advanced NSCLC.4 Sanofi and Regeneron developed Libtayo and partnered with Agilent for the use of PD-L1 IHC 22C3 pharmDx to evaluate PD-L1 expression in patients in the pivotal EMPOWER-Lung 1 (Study 1624)clinical trial.4

Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.4

References:
1. World Health Organization. Global Cancer Observatory. https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf (accessed February 26, 2021).
2. Wood, R.; Taylor-Stokes, G.; Smith, F.; Chaib, C. The Humanistic Burden of Advanced Non-Small Cell Lung Cancer (NSCLC) in Europe: A Real-World Survey Linking Patient Clinical Factors to Patient and Caregiver Burden. Qual. Life Res. 2019, 28 (7), 1849-1861.
3. Lung Cancer Europe. 4th LuCE report on lung cancer: Early diagnosis and screening challenges in lung cancer. https://www.lungcancereurope.eu/wp-content/uploads/2019/11/WEB-VERSION-IV-LuCE-Report.pdf.pdf (accessed June 24, 2021).
4. Libtayo [Summary of Product Characteristics]. European Medicines Agency; 2021
.

Disclaimer

Agilent Technologies Inc. published this content on 20 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2021 16:15:05 UTC.


ę Publicnow 2021
All news about AGILENT TECHNOLOGIES, INC.
11/23Agilent to Present at Evercore ISI Virtual Healthcare Conference
BU
11/23Stifel Adjusts Price Target for Agilent Technologies to $169 From $162, Maintains Hold ..
MT
11/23SVB Leerink Adjusts Agilent Technologies' Price Target to $175 from $170, Keeps Outperf..
MT
11/23Health Care Stocks Flat Ahead of Tuesday's Opening Bell
MT
11/22AGILENT TECHNOLOGIES : Prepared Remarks (opens in new window)
PU
11/22AGILENT : Fiscal Q4 Earnings Snapshot
AQ
11/22Agilent Technologies Fiscal Q4 non-GAAP EPS, Revenue Rise
MT
11/22AGILENT TECHNOLOGIES : Reports Fourth-Quarter and Fiscal Year 2021 Financial Results - For..
PU
11/22Earnings Flash (A) AGILENT TECHNOLOGIES Posts Q4 Revenue $1.66B, vs. Street Est of $1.6..
MT
11/22Agilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Results
BU
More news
Analyst Recommendations on AGILENT TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2021 6 318 M - -
Net income 2021 1 075 M - -
Net Debt 2021 1 485 M - -
P/E ratio 2021 42,8x
Yield 2021 0,51%
Capitalization 45 206 M 45 206 M -
EV / Sales 2021 7,39x
EV / Sales 2022 6,82x
Nbr of Employees 17 000
Free-Float 100,0%
Chart AGILENT TECHNOLOGIES, INC.
Duration : Period :
Agilent Technologies, Inc. Technical Analysis Chart | A | US00846U1016 | MarketScreener
Technical analysis trends AGILENT TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 149,33 $
Average target price 173,80 $
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
Michael R. McMullen President, Chief Executive Officer & Director
Robert W. McMahon Chief Financial Officer & Senior Vice President
Boon Hwee Koh Non-Executive Chairman
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Katharine Knobil Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGILENT TECHNOLOGIES, INC.25.08%45 206
THERMO FISHER SCIENTIFIC36.57%250 658
DANAHER CORPORATION40.88%223 620
INTUITIVE SURGICAL, INC.20.03%114 898
SIEMENS HEALTHINEERS AG52.50%80 761
EDWARDS LIFESCIENCES CORPORATION20.38%67 728